Literature DB >> 2193641

Two-phase [11C]L-methionine PET in childhood brain tumors.

L A O'Tuama1, P C Phillips, L C Strauss, B C Carson, Y Uno, Q R Smith, R F Dannals, A A Wilson, H T Ravert, S Loats.   

Abstract

Thirteen children (1.8-15.8 years of age) with brain tumors were studied with [11C]L-methionine positron emission tomography (METPET). Patients were injected intravenously with tracer before a baseline PET scan was obtained. To assess the sensitivity of [11C]L-methionine uptake to competitive inhibition, 10 patients received oral L-phenylalanine (100 mg/kg); 1 hour later, a second METPET was obtained. Subjective assessment of [11C]L-methionine uptake closely paralleled results of quantitative examination (r = 0.81). [11C]L-methionine uptake in tumor-containing brain was increased in 11 patients (mean ratio of [11C] radioactivity in tumor to normal brain: 1.5 +/- 0.57; range: 1.13-2.98). Increased tracer uptake occurred in ependymomas (3), medulloblastoma (1), and astrocytomas (5), but was less intense in low-grade tumors. L-phenylalanine reduced L-methionine uptake (25-69%) in 70% of studies. L-methionine uptake was not sensitive to competitive inhibition in brain radiation injury. Two-phase METPET is of potential value in difficult clinical situations evident in children with brain tumors, including the differential diagnosis of tumor recurrence and cerebral radiation injury.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2193641     DOI: 10.1016/0887-8994(90)90057-8

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  12 in total

Review 1.  Positron emission tomography and the central nervous system.

Authors:  R O Robinson; C D Ferrie; M Capra; M N Maisey
Journal:  Arch Dis Child       Date:  1999-09       Impact factor: 3.791

2.  Association of rubidium and C-methionine uptake in brain tumors measured by positron emission tomography.

Authors:  U Roelcke; E Radü; S Ametamey; R Pellikka; W Steinbrich; K L Leenders
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

3.  High amino acid uptake in a low-grade desmoplastic infantile ganglioglioma in a 14-year-old patient.

Authors:  B Woesler; T Kuwert; G Kurlemann; C Morgenroth; S Probst-Cousin; H Lerch; F Gullotta; H Wassmann; O Schober
Journal:  Neurosurg Rev       Date:  1998       Impact factor: 3.042

4.  Evaluation of the biodistribution of 11C-methionine in children and young adults.

Authors:  Sebastian M Harris; James C Davis; Scott E Snyder; Elizabeth R Butch; Amy L Vavere; Mehmet Kocak; Barry L Shulkin
Journal:  J Nucl Med       Date:  2013-09-19       Impact factor: 10.057

Review 5.  Where are we with nuclear medicine in pediatrics?

Authors:  H R Nadel
Journal:  Eur J Nucl Med       Date:  1995-12

Review 6.  Imaging in neurooncology.

Authors:  Andreas H Jacobs; Lutz W Kracht; Axel Gossmann; Maria A Rüger; Anne V Thomas; Alexander Thiel; Karl Herholz
Journal:  NeuroRx       Date:  2005-04

Review 7.  Neuroradiology of pediatric posterior fossa medulloblastoma.

Authors:  S I Blaser; D C Harwood-Nash
Journal:  J Neurooncol       Date:  1996-07       Impact factor: 4.130

8.  Affinity of antineoplastic amino acid drugs for the large neutral amino acid transporter of the blood-brain barrier.

Authors:  Y Takada; N H Greig; D T Vistica; S I Rapoport; Q R Smith
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

9.  The impact of PET scanning on management of paediatric oncology patients.

Authors:  E A Wegner; S F Barrington; J E Kingston; R O Robinson; R E Ferner; M Taj; M A Smith; M J O'Doherty
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-31       Impact factor: 9.236

10.  [11C]-L-methionine positron emission tomography in the management of children and young adults with brain tumors.

Authors:  Norbert Galldiks; Lutz W Kracht; Frank Berthold; Hrvoje Miletic; Johannes C Klein; Karl Herholz; Andreas H Jacobs; Wolf-Dieter Heiss
Journal:  J Neurooncol       Date:  2009-07-04       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.